Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734425 | 0.91 | PDE4A (0.39) | SQORRAB9AAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL2819362 | 0.88 | SQOR (0.38) | SQORSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL2819395 | 0.84 | MET (0.43) | SQORKDRMETSMN1; SMN2LMNA | |
| SCHEMBL2819107 | 0.83 | GAA (0.46) | IKBKBSQORKDRMETCA9 | |
| SCHEMBL3737061 | 0.83 | SQOR (0.39) | IKBKBSQORSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2822812 | 0.82 | IKBKB (0.40) | IKBKBSQORKDRMETCA9 | |
| SCHEMBL2817714 | 0.80 | DGAT1 (0.44) | IKBKBKDRSMN1; SMN2LMNAMAPT | |
| SCHEMBL2816056 | 0.80 | IKBKB (0.47) | IKBKBSQORKDRMETRAB9A | |
| SCHEMBL2821100 | 0.79 | KDR (0.43) | KDRMETRAB9ASMN1; SMN2MAPT | |
| SCHEMBL2816429 | 0.78 | SQOR (0.51) | IKBKBSQORKDRMETGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| EP-2032572-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7825114-B2 | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825114-B2 | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-2061790-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-27 | — | — | EP | disclosed |
| EP-2032572-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20090018129-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018129-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007144202-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144202-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144204-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144204-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | IKBKB 1240/4885SQOR 1260/4885KDR 1/4885 |
| US-20090018129-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, TEK | IKBKB 903/4885SQOR 1753/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.